Phathom Pharmaceuticals (PHAT) Finished Goods (2023 - 2026)

Phathom Pharmaceuticals (PHAT) has 4 years of Finished Goods data on file, last reported at $1.5 million in Q1 2026.

• Finished Goods for Q1 2026 came in at $1.5 million, down 14.09% year-over-year; the trailing twelve-month figure through Mar 2026 was $1.5 million (down 14.09% YoY), and the FY2025 annual result was $1.5 million, down 1.49% from the prior year.
• Finished Goods climbed to $1.5 million in Q1 2026 per PHAT's latest filing, from $1.5 million in the prior quarter.
• Over five years, Finished Goods peaked at $2.6 million in Q3 2025 and troughed at $647000.0 in Q4 2023.
• A 4-year average of $1.5 million and a median of $1.5 million in 2024 frame the typical range for Finished Goods.
• The sharpest annual moves came in 2025 and 2026: Finished Goods jumped 177.27% in 2025, then retreated 14.09% in 2026.
• A 4-year view of Finished Goods shows it stood at $647000.0 in 2023, then jumped by 128.59% to $1.5 million in 2024, then decreased by 1.49% to $1.5 million in 2025, then climbed by 1.72% to $1.5 million in 2026.
• Business Quant data shows PHAT's Finished Goods at $1.5 million in Q1 2026, $1.5 million in Q4 2025, and $2.6 million in Q3 2025.